Treatment of HER2-Low Breast Cancer Impacts Oncology Landscape
Because of its prevalence in approximately 50% of breast cancers, the outcomes of HER2-low treatment have a significant impact on patient outcomes.
Because of its prevalence in approximately 50% of breast cancers, the outcomes of HER2-low treatment have a significant impact on patient outcomes.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible…
Walking is a simple exercise that has many health benefits. Karen Basen-Engquist, Ph.D., shares tips on walking as exercise and how to increase the amount…
James Cribbin and his wife, Alexandra, came to MD Anderson for its expertise in marginal zone lymphoma, a rare subtype of non-Hodgkin lymphoma. What they…
Even if you’re in remission or you show no evidence of disease, you may still have fears that cancer may return. We spoke with our…
Apple cider vinegar, a liquid made from fermenting apples, is said to have many potential health benefits. But what does research say about these claims?…
Virtual nursing is transforming patient care and enhancing how MD Anderson supports its oncology nurses. Here’s how.
What’s new in the treatment of prostate cancer with immunotherapy? Urologic oncologist Bilal Siddiqui, M.D., weighs in.
Ascites are abnormal pockets of fluid that develop in the abdomen. We spoke to gynecologic oncologist Travis Sims, M.D., to learn more about this late-stage…
Lucy Bujnoch and her two kids, Mike Gonzalez and Rebecca Bujnoch, each have a different role at MD Anderson but work in the same department.
Sarah Wilder wanted a way to give back while her husband received treatment at MD Anderson for stage IV prostate cancer. A blood drive provided…